Guardant Health Announces Board and Executive Changes

Ticker: GH · Form: 8-K · Filed: 2025-09-15T00:00:00.000Z

Sentiment: neutral

Topics: management-change, executive-compensation, board-of-directors

TL;DR

Guardant Health shakes up its board and exec pay structure. Big changes coming?

AI Summary

Guardant Health, Inc. announced on September 12, 2025, changes in its board of directors and executive compensation. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific details regarding the individuals involved and the exact nature of the compensation changes are outlined within the report.

Why It Matters

Changes in leadership and executive compensation can signal shifts in company strategy or financial health, impacting investor confidence and stock performance.

Risk Assessment

Risk Level: medium — Changes in directors and officers, along with compensatory arrangements, can indicate internal shifts that may affect future performance and strategy.

Key Players & Entities

FAQ

Who are the specific directors or officers departing from Guardant Health?

The filing indicates the departure of certain officers and directors, but the specific names are detailed within the full report under Item 5.02.

What are the new compensatory arrangements for the officers?

The filing refers to updates in compensatory arrangements for certain officers, with specific details provided in the full document under Item 5.02.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on September 12, 2025.

What is the primary business of Guardant Health, Inc. according to the filing?

Guardant Health, Inc. is classified under SERVICES-MEDICAL LABORATORIES [8071].

What items are being reported in this Form 8-K?

This Form 8-K reports on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; and Financial Statements and Exhibits.

From the Filing

0001576280-25-000267.txt : 20250915 0001576280-25-000267.hdr.sgml : 20250915 20250915161112 ACCESSION NUMBER: 0001576280-25-000267 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250912 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250915 DATE AS OF CHANGE: 20250915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 251314428 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 gh-20250912.htm 8-K gh-20250912 0001576280 false 0001576280 2025-09-12 2025-09-12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): September 12, 2025 GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-38683 45-4139254 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.00001 par value per share GH The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On September 12, 2025, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to 11 and appointed Alex M. Azar II, former United States Secretary of Health and Human Services, as a Class III director of the Company, to be effective as of September 12, 2025. Secretary Azar will serve on the Board for a term expiring at the 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. In connection with his appointment to the Board, Secretary Azar was

View on Read The Filing